Skip to main content
CRISPR Therapeutics AG logo

CRISPR Therapeutics AG — Investor Relations & Filings

Ticker · CRSP ISIN · CH0334081137 LEI · 506700O6IRRIQLT3W370 US Manufacturing
Open in API
Filings indexed 821 across all filing types
Latest filing 2018-12-03 Director's Dealing
Country CH Switzerland
Listing US CRSP

About CRISPR Therapeutics AG

https://crisprtx.com/

CRISPR Therapeutics AG is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. The company leverages this technology to make precise, directed changes to genomic DNA. As a pioneer in the field, CRISPR Therapeutics has established a diverse portfolio of therapeutic programs across several disease areas, including hemoglobinopathies (such as sickle cell disease and beta-thalassemia), immuno-oncology, regenerative medicine, and cardiovascular disease. The company was one of the first to advance a CRISPR-based therapy into clinical trials and receive regulatory approval, aiming to create potentially curative treatments for patients.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2018-12-03 English
Regulatory Filings 2018
Regulatory Filings
2018-11-30 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content describes the issuance of common shares to ViaCyte, Inc. under a collaboration agreement, referencing a shelf registration statement and including a legal opinion as an exhibit. There are no financial statements or detailed financial results presented, nor is this an annual or quarterly report. The primary focus is on a capital issuance event. Therefore, this filing is best classified as a Capital/Financing Update (CAP). The document length is 3047 characters, which is consistent with a typical 8-K filing for such an event, not a full report or announcement of a report publication.
2018-11-09 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a share offering. It details the terms of a share issuance to ViaCyte, Inc. under a Research Collaboration Agreement, including the number of shares, pricing, and related legal and risk disclosures. The document is a registration and offering prospectus supplement, which is a type of capital raising disclosure. It is not a financial report, earnings release, management discussion, or any other report type. It is clearly an update on capital raising and share issuance activity. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial and contains detailed offering information, not just an announcement or link to a report, so it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS).
2018-11-08 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 7, 2018, reporting the financial results for the third quarter ended September 30, 2018. It includes a press release as Exhibit 99.1 announcing the quarterly financial results. The text explicitly states it is a current report on Form 8-K and the content is a press release of financial results, which corresponds to an Earnings Release. The document length is 3315 characters, which is short and typical for an earnings release announcement rather than a full interim report. Therefore, the appropriate classification is Earnings Release (ER).
2018-11-07 English
10-Q
Interim / Quarterly Report Q3 2018
2018-11-07 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.